Chemistry:Oritinib
From HandWiki
Oritinib is an investigational new drug currently under investigation for its potential use in cancer treatment.[1][2] As a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, oritinib targets specific enzymes involved in the signaling pathways that regulate cell division and survival, which are often dysregulated in cancer cells.[1]
References
- ↑ 1.0 1.1 "Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial". Journal of Thoracic Oncology 17 (10): 1216–1226. October 2022. doi:10.1016/j.jtho.2022.06.013. PMID 35798241.
- ↑ "Rilertinib - Nanjing Sanhome Pharmaceutical". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800052633.
 |  |
